RPRX logo

RPRX Royalty Pharma plc - Ordinary Shares - Class A

$57.16
$0.47
(0.82%)
Today
Closed $57.16
$0.00
(0.00%)
After Hours
56

Bullish Sentiment

How do you feel about RPRX?

Loading...
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Key PointsRoyalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates...
Nasdaq News: Markets
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.61%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Key PointsRevolution Medicines has just received good news around a drug meant to treat pancreatic cancer...
Nasdaq News: Markets
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Zacks
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annualized basis producing an average annual return of 18.08%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.read more...
Benzinga
Watch These 2 Energy Stocks — S&P 500 Addition Could Come Before Quarter's End
Bloom Energy and Cheniere Energy are two of the most likely inclusions in the benchmark index, according to Stephens analyst Melissa Roberts.
Stocktwits
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.
Stocktwits